Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

EGFR is a potential dual molecular target for cancer and Alzheimer’s diseaseopen access

Authors
Choi, Hee-JeongJeong, Yoo JooKim, JieunHoe, Hyang-Sook
Issue Date
Aug-2023
Publisher
Frontiers Media SA
Keywords
Alzheimer' s disease; EGFR; EGFR inhibitor; cancer; A beta; learning and memory
Citation
Frontiers in Pharmacology, v.14
Journal Title
Frontiers in Pharmacology
Volume
14
URI
http://scholarworks.bwise.kr/kbri/handle/2023.sw.kbri/972
DOI
10.3389/fphar.2023.1238639
ISSN
1663-9812
Abstract
Many researchers are attempting to identify drugs that can be repurposed as effective therapies for Alzheimer's disease (AD). Several recent studies have highlighted epidermal growth factor receptor (EGFR) inhibitors approved for use as anti-cancer drugs as potential candidates for repurposing as AD therapeutics. In cancer, EGFR inhibitors target cell proliferation and angiogenesis, and studies in AD mouse models have shown that EGFR inhibitors can attenuate amyloid-beta (A beta) pathology and improve cognitive function. In this review, we discuss the different functions of EGFR in cancer and AD and the potential of EGFR as a dual molecular target for AD diseases. In addition, we describe the effects of anti-cancer EGFR tyrosine kinase inhibitors (TKIs) on AD pathology and their prospects as therapeutic interventions for AD. By summarizing the physiological functions of EGFR in cancer and AD, this review emphasizes the significance of EGFR as an important molecular target for these diseases.
Files in This Item
There are no files associated with this item.
Appears in
Collections
연구본부 > 퇴행성 뇌질환 연구그룹 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Hoe, Hyang Sook photo

Hoe, Hyang Sook
연구본부 (퇴행성뇌질환 연구그룹)
Read more

Altmetrics

Total Views & Downloads

BROWSE